Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma 31Lymphoma, Large B-Cell, Diffuse 28Burkitt Lymphoma 18Prostatic Neoplasms 16Lymphoma, Non-Hodgkin 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Multiple Myeloma 12Lymphoma, Follicular 11Leukemia 11Hodgkin Disease 8Lymphoma, Mantle-Cell 7Neoplasms, Plasma Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 4Myelodysplastic Syndromes 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Plasmablastic Lymphoma 3Lymphoproliferative Disorders 3Lymphoma, T-Cell 3Lymphoma, Primary Effusion 3Lymphoma, AIDS-Related 3Hematologic Neoplasms 3HIV Infections 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Castrate Sensitive Prostate Cancer × Prednisone × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡